以前接受过治疗的患有表皮生长因子受体突变的高级非小细胞肺癌患者的未满足需求和治疗期望:定性访谈研究
Jyoti D Patel1, Jie Meng2, Aura Cecilia Jimenez-Moreno3
1Northwestern University Feinberg School of Medicine, Chicago, IL.
Clinical lung cancer
|March 14, 2026
概括
患有EGFR突变的晚期非小细胞肺癌 (NSCLC) 的患者会出现显著的症状和情绪困扰. 在新疗法中,他们优先考虑改善生活质量和延迟疾病进展.
科学领域:
- 在瘤学瘤学.
- 患者报告的结果
- 翻译研究是翻译研究.
背景情况:
- 对于先前治疗过EGFR突变的先进非小细胞肺癌 (NSCLC) 的治疗效果有限.
- 未满足的患者需求和治疗期望对于指导药物开发至关重要.
研究的目的:
- 了解EGFR突变晚期NSCLC患者的未满足需求和治疗期望,这些患者在osimertinib治疗中进展.
- 确定这一患者群体中关键的症状负担和生活质量影响.
主要方法:
- 与37名美国,英国,德国,西班牙和意大利的患者进行了定性访谈.
- 采访成绩单的内容分析.
- 评估生活质量 (EQ-5D-5 L) 和NSCLC症状.
主要成果:
- 所有患者报告呼吸道症状 (如疲劳);97%报告多次.
- 54%的受访者表示无法进行体力活动;62%的受访者表示焦虑/忧虑.
- 改善生活质量 (76%) 和减缓疾病进展 (71%) 是治疗的主要目标.
结论:
- 以前接受过治疗的EGFR突变高级NSCLC患者面临着相当大的症状负担和情绪困扰.
- 患者期望得到改善生活质量和延缓疾病进展的治疗方法.
更多相关视频
07:59Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
1.8K
09:38Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
8.5K
相关概念视频
Mitogens and the Cell Cycle
8.3K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.3K
Treatment Resistent Cancers
1.5K
1.5K
Targeted Cancer Therapies
9.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
9.1K
Treatment Resistant Cancers
3.9K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
532
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
532
